The lack of HLA class I antigen expression by the melanoma cell line SK-MEL-33 is caused by a unique lesion in p2-microglobulin (02-M). Sequencing of 2-A mRNA detected a guanosine deletion at position 323 in codon 76 that causes a frameshift with a subsequent introduction of a stop codon at a position 54 base upstream of the normal position of the stop codon in the message. The loss of 18 amino acids and the change of 6 amino acids, including a cysteine at position 80 in the carboxy terminus of fl2-M, are likely to cause marked changes in the structure of the polypeptide. The latter may account for the inability of 02-M to associate with HLA class I heavy chains and for its lack of reactivity with the anti-iB2-M mAb tested. HLA class I antigen expression on SK-MEL-33 cells was reconstituted after transfection with a wild-type B2m gene, therefore indicating that the abnormality of endogenous B2m gene is the only mechanism underlying lack of HLA class I antigen expression by SK-MEL-33 cells. The guanosine deletion in B2m gene was detected also in the melanoma tissue from which SK-MEL-33 cells had originated. Therefore, the molecular lesion identified in the SK-MEL-33 melanoma cell line is not caused by a mutation acquired during growth in vitro but is likely to reflect a somatic mutation during tumor progression. (J. Clin. Invest. 1993. 91:684-692.)
Introduction
Malignant transformation ofhuman melanocytes may be associated with changes in their antigenic profile. The latter include reduction or loss of HLA class I antigen expression, which has been found to occur in -30% of surgically removed melanoma lesions (for review, see reference 1). Abnormalities in HLA class I antigen expression are likely to affect the biology of melanoma cells and their interactions with immune cells be-cause of the role of HLA class I antigens in cell proliferation (2) (3) (4) , interaction of target cells with cytotoxic T cells (for review see reference 5) , and susceptibility of malignant cells to natural killer (NK)' cell-mediated lysis (for review see reference 6). Besides contributing to the characterization of the machinery regulating HLA class I antigen synthesis and expression, analysis of the molecular mechanisms underlying reduction or loss of HLA class I antigen expression by melanoma cells provides the necessary background to correct these abnormalities. This information may eventually be used to develop therapeutic approaches to melanoma, if the association between poor prognosis and reduction or lack of HLA class I antigen expression in melanoma lesions (7) reflects their role in the clinical course of the disease.
In a recent study we have shown that melanoma cells FO-1 do not express HLA class I antigens because of a gross deletion ofthe 5' region and a portion ofthe coding sequence ofthe B2m gene that prevents its transcription ( 8 ) . In the present study, we have characterized the molecular defect that accounts for the lack of HLA class I antigen expression by melanoma cells SK-MEL-33.
Methods
Patient. Patient AZ was a 74-yr-old white male who had a lentigo maligna melanoma excised from the skin of his right scapula in 1972. Two years later, in January 1974, a mass appeared in the left axilla. The mass was excised and revealed metastatic melanoma involving regional lymph nodes. A large (5 X 4 X 4 cm), firm mass reappeared at the apex of the left axilla in June 1974. The patient underwent a deep axillary lymph node dissection. Pathological examination showed metastatic melanoma within lymph nodes invading the surrounding subcutaneous tissue, fat, pectoralis minor muscle, brachial nerve plexus, and brachial vein. The melanoma cell line SK-MEL-33 was established from this lesion. The patient remained free ofany recurrent melanoma for 2 10 yr. He was last seen for follow-up in 1983 when he was 85 yr old. Clinical staging at that time demonstrated no evidence ofrecurrent melanoma on physical examination, chest x ray, and liver function tests.
Cell lines, tumor specimen, and j32-microglobulin (132-M). The melanoma cell line SK-MEL-33 was cultured in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY) supplemented with 10% FCS, 2 mM L-glutamine, and 1% nonessential amino acids. The melanoma cell lines FO-1, Colo 38 and 3S5 and the B lymphoblastoid cell line MANN were grown in RPMI 1640 medium supplemented with 10% Serum Plus (Hazelton Biologics, Inc., Lenexa, KS) and 2 mM L-glutamine. Cells were harvested by vigorous pipetting with PBS supplemented with 1 mM EDTA.
The formalin-fixed and paraffin-embedded specimen ofthe human malignant melanoma lesion (Clark's level IV), from which the cell line SK-MEL-33 was originally established, was retrieved from the files of the Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York. The tumor had been fixed in 10% formalin (formaldehyde 4% vol/wt, methyl alcohol 1% vol/wt, buffered with phosphate buffer) (Mallinckrodt Chemical Works, NY) for 24 h before embedding into paraffin. One section was cut for standard hematoxylin and eosin staining and three adjacent 20-.um thick sections containing only tumor were cut for DNA isolation. Lesional portions of the two unstained sections were scraped with a stainless steel spatula into a 1.5 ml Eppendorf tube.
#2-u was purified from urine as described (9) . mAb and conventional antisera. The mAb W6/32 to a monomorphic determinant expressed on #2-g-associated HLA class I heavy chains (10); the mAb TP25.99 to a determinant expressed on both h2-IA-associated and 32-M-free HLA class I heavy chains (8) ; the antihuman #2-$ mAb BBM-1 (11), L368 (12) , and NAMB-I (13); the anti-HLA-DR, DQ, DP mAb Q5/13 (14) ; and the antiintercellular adhesion molecule-l (ICAM-1) mAb CL207.14 (15) were developed and characterized as described. mAbs were purified from ascitic fluid by sequential precipitation with caprylic acid and ammonium sulphate ( 16 ) . mAbs were labeled with 125I using the iodogen method ( 17 ) . The immunoreactive fraction of the radiolabeled antibodies was at least 50% as determined by the method of Lindmo et al. ( 18) .
The rabbit antiserum R5996-4 reacting with denatured HLA class I heavy chain and the rabbit anti-human (2-M antiserum DP-213456 were prepared by following the methodology described by Nakamuro et al. (19) and by Poulik et al. (20) , respectively. Anti-human #2-u antibodies were purified from rabbit antiserum DP-2 13456 by affinity chromatography on purified #2-u coupled to AFFI-GEL 10 (Bio-Rad Laboratories, Richmond, CA) (1 mg/ml of gel). Purified goat anti-rabbit Ig antibodies and rabbit anti-mouse Ig antibodies were purchased from Jackson ImmunoResearch Laboratories, Inc. (Avondale, PA).
cDNA probes, B2m gene, and oligonucleotides. The cDNA probes for human #2-M (21) and for HLA-B7 antigen (22) were isolated by digestion of plasmids with restriction endonuclease PstI. The inserts were electrophoresed and excised from low melting agarose gel. Human B2m clone pb2m 13 in the vector pEMBL9 (23) was purified on a CsCl gradient and digested either with XbaI alone or with the combination of HindIII and XbaI or of EcoRI and SmaI. An upstream 5' fragment (referred to as probe A), the first exon and much of its flanking sequences (referred to as probe B), the second and third exons and their flanking sequences (referred to as probe C), and the fourth exon and its flanking sequences (referred to as probe D) were separated by electrophoresis on a low melting point agarose gel as described (8 Radiolabeling of cells, indirect immunoprecipitation, and SDS-PAGE. These procedures were performed as described elsewhere (8) .
Cells were labeled with '25I (Amersham Corp.) using the lactoperoxidase method (26) or with [33S methionine (Amersham Corp.). Then cells were solubilized by incubation for 30 min at 4VC in lysis buffer containing 1% Nonidet P-40, 10 mM Tris-HCl, pH 8.2,0.5 M NaCl, 1 mM EDTA, 1 mg/ml BSA, and 1 mM PMSF and incubated for 12 h at 4°C with antibodies bound to protein A Sepharose (Pharmacia Inc., Piscataway, NJ). One-dimensional SDS-PAGE analysis was performed under reducing conditions in slab gels containing 12.5% acrylamide and using the buffer system described by Laemmli (27) . Gels containing '25I-labeled samples were processed for autoradiography using Kodak XAR-5 film (Eastman Kodak Co., Rochester, NY). Gels containing [35S]methionine-labeled samples were processed for fluorography as described (28) .
Preparation of total mRNA and poly A+ RNA. Total RNA was isolated from cells using the method described by Geliebter et al. (29) . Poly(A)-containing RNA was purified by chromatography on oligo(dT) cellulose (Boehringer Mannheim Corp., Indianapolis, IN).
Preparation ofDNA from paraffin tissue sections. Tissue sections were incubated in xylene to dissolve the paraffin. The tissue was then pelleted by centrifugation at 12,000 g for 5 min (30, 31 ) . The supernatant was discarded and after two additional incubations with xylene the pellet was washed sequentially with 100% and 70% ethanol. The pellet was resuspended in 100 ,l ofa digestion buffer (0.2 M Tris-HCl, pH 8; 10 mM EDTA, 1% SDS) to which Proteinase K stored at -20°C was added to a final concentration of 0.5 mg/ml. At the end of a 48-h incubation at 55°C, more SDS and freshly thawed Proteinase K were added to the reaction mixture to a final concentration of 2% and 1 mg/ml, respectively. Incubation was continued for an additional 25 h at 55°C. The sample was then heated to 95°C for 6 min to inactivate Proteinase K and was extracted twice with phenol-chloroform. Finally, DNA was precipitated in 0.3 M NaCl and 100% ethanol at -70°C for 12 h and pelleted by centrifugation at 12,000 g for 30 min. The pellet was washed twice with 70% ethanol and resuspended in 100 /d of filtered and autoclaved water.
RNA hybridization analysis. Total RNA was size fractionated in a 1% agarose gel containing 2.2 M formaldehyde, transferred to a nitrocellulose membrane, and hybridized with 32P-labeled probes as described (8) .
DNA hybridization analysis. Genomic DNA was extracted essentially as described by Perbal (32) . DNA was digested with restriction endonucleases, size fractionated, transferred to nitrocellulose membrane, and hybridized as described previously (8) . When 32P-labeled specific oligonucleotides for the B2m gene were used as probes, the hybridization was performed at a temperature 5°C below the calculated melting temperature as described (33) .
RNA sequencing. #2-A mRNA was sequenced by following the methodology described by Geliebter et al. (25) . Briefly, 32P-labeled oligonucleotide primers (10 ng) and poly AI RNA (20 Ig) were heated to 80°C for 3 min in 15 ,ul of annealing buffer (250 mM KCI, 10 mM Tris-HCl, pH 8.3, 1 mM EDTA) and incubated for 60 min at 60°C or at 45°C. The dideoxynucleotides diluted with dH2O in different ratio and 3.3 ul of reverse transcriptase diluted in extension buffer (24 mM Tris-HCl, pH 8.3, 10 mM MgCI2, 8 mM dithiothreitol, 0.2 mM dATP, 0.2 mM dCTP, 0.2 mM dTTP, 0.2 mM dGTP) were added into RNA primer-annealing solution, mixed, and incubated for 60 min at 500C. Reactions were terminated by adding 2 y1 of loading buffer (100% formamide, 0.3% xylene cyanol F, 0.3% bromophenol blue). Samples were electrophoresed in 6% polyacrylamide, 8 M urea gel at 17-18 V. After electrophoresis, gels were dried and exposed to Kodak XAR-5 film (Eastman Kodak Co.) for 72 h at -70'C. Nucleotide sequences were translated into amino acid sequences by using the software microgenie (Version 7.0, Beckman Instruments, Inc., Fullerton, CA).
In vitro amplification ofgenomic DNA. Extracted DNA was used as a template for amplification using the Thermus aquaticus (TaqI) heatstable DNA polymerase as described (34) . Amplifications were performed in siliconized tubes (Biomedica, Rutherford, NJ) in a 50-,41 solution containing genomic DNA template, 50 mM KCl, 10 mM Tris, pH 8.4, 2.5 mM MgCl2, 300 ng of primer 1 and primer 2, 200 gM of each deoxyribonucleotide triphosphate (dATP, dCTP, dTTP, and dGTP), 100 Ag of gelatin/ ml, and 3 U of Taql DNA polymerase (Perkin-Elmer Cetus Instruments, Norwalk, CT). Samples were overlaid with 50 ,l ofmineral oil to prevent condensation and were subjected to 35 cycles of amplification. The cycling reaction was performed in a programmable heat block (DNA Thermal Cycler; Perkin-Elmer Cetus Instruments) set to heat samples to 94°C for 1 min, cool them to 50°C over 1 min, and heat them to 73°C for 1 min. In the first cycle DNA was denatured at 94°C for 5 min. Amplified DNA was analyzed by nondenaturing agarose gel electrophoresis. 5 Al of the amplification reaction was electrophoresed on a 1.5% Tris-Borate-EDTA agarose gel (FMC Corp., Rockland, ME) in the presence of ethidium bromide.
Cloning and sequencing ofPCR products. B2m PCR products were ligated into plasmid vector PCR (Invitrogen, San Diego, CA) and used to transform competent bacteria (Escherichia coli INVaF'). Single colonies of transformed bacteria were selected in medium containing kanamycin (50 Mg/ ml) and grown to mass culture. Amplified plasmid was extracted according to established protocols (35) and used in direct DNA sequencing reactions using the chain-termination technique (36) with a modified T7 DNA polymerase (37), (Sequenase 2.0; United States Biochemical Corp., Cleveland, OH). Plasmid DNA (2.5 ,g) was incubated with 10 ng of M13(-)20 Primer-(5'-GTAAAAC-GACGGCCAGT-3') (Stratagene, Inc., La Jolla, CA) in 0.25 N NaOH at 20°C for 5 min. Denatured plasmid and annealed primer mixture were then precipitated with 5 M ammonium acetate, pH 4.6, and ethanol and were centrifuged at 15,000 g for 15 min. Pellets were washed with 70% ethanol, recentrifuged, dried, and resuspended in 8 Ml of water. The annealed primer/template mixture was supplemented with 1 Ml 0.1 M DDT, 1 Ml 10 mU [a-35S]dATP ( 1,000 Ci/mmol; New England Nuclear, Boston, MA), 2 Ml dilute labeling mixture ( 1:5), and 3 U of Sequenase 2.0 (United States Biochemical Corp.). The reaction mixture was mixed, incubated for 2 min at room temperature, and aliquoted into four tubes containing 2.5 ,l of the respective deoxy/dideoxy termination mixture (80MM dATP, 80MM dCTP, 80MUM dGTP, 80 MM dTTP, and 8 MM of the respective dideoxy nucleotide triphosphate). After a 10-min incubation at 37°C, 4 Ml of stop buffer (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol) was added to each tube. Tubes were then heated to 94°C for 2 min. The reaction mixture was loaded on an 8% polyacrylamide-8 M urea gel and run for 4 h at constant wattage.
Transfection of SK-MEL-33 melanoma cells with a wild-type human B2m gene. The procedure we used previously (8) was followed with minor modifications. Briefly, cells (1 X I07), linearized human B2m DNA fragment (100 ,g), and EcoRI-digested pSV2neo (5 Mg) were suspended in 1 ml of cold PBS. An electroporation power supply (Bethesda Research Laboratories, Gaithersburg, MD) applied an electric pulse of 1 kV and 330 MF to the chamber containing cells. Cells were then recovered in RPMI 1640 medium supplemented with 10% FCS, seeded in eight 100-mm tissue culture dishes, and incubated at 37°C in 5% CO2 for 7 d. On day 8, G418-sulfate was added to the medium at the final concentration of 2 mg/ml. The concentration of G418-sulfate was reduced to 0. Fig. 1) . No reactivity with these mAbs was detected also after incubation ofcells with IFN-'y (1,000 U/ml) for 3 d before testing (Fig. 1) . Further anti-fl2-A polyclonal antibodies isolated from rabbit anti-fl2-,g serum DP-2 13456. Antigens were then eluted from the immunoabsorbent and analyzed by SDS-PAGE in the presence of 2% fl-mercaptoethanol. Gels were then processed for fluorography (27) . (Fig. 3) . The intensity of I2-A mRNA hybridized with radiolabeled 12-/ cDNA probe was lower than in melanoma cells Colo 38 and 3S5; it was markedly increased when RNA was extracted from IFN-'y-treated SK-MEL-33 cells (Fig. 3) . Furthermore, Northern blot analysis of RNA isolated from SK-MEL-33 cells treated with actinomycin D (final concentration 5 ,gg/ml) for < 2 h detected no abnormality in the stability of (2-A mRNA (data not shown). Lastly, Southern blot analysis using four DNA fragments isolated from B2m gene clone pb2m 13 (8, 23) as probes detected no difference in the restric- homology between themselves and of at least 98.6% with the published sequence of pb2m 13 (Fig. 4) (Fig. 6) . These results corroborate the sequencing data that guanosine was deleted at position 323 (in codon 76) in I2-JU mRNA of SK-MEL-33 cells.
The guanosine deletion causes a frameshift with a subsequent introduction of a stop codon at a position 54 bases upstream ofthe normal position ofthe stop codon in the message (Fig. 4) . This results in the translation of a truncated protein that is 18 amino acids shorter than the wild-type #2-g protein.
Furthermore, the changes from codon 76 to codon 81 result in the substitution ofthe corresponding six amino acids. Ofgreat significance in terms of the overall structure of #2-.t, is the replacement with an alanine ofa cysteine that is at position 80 in the #2-$ polypeptide.
#2-Microglobulin Gene Base Deletion in Melanoma Cells 689
Detection ofa guanosine deletion in #2-j. in melanoma tissue from which the SK-MEL-33 cell line had originated. To determine whether the base deletion detected in SK-MEL-33 cells was present in the lesion from which the cell line had originated, DNA extracted from the melanoma lesion was used for PCR amplification with primers specific for the second exon of the human gene. Approximately 200 bases of the amplified region ofthis gene were sequenced. The guanosine deletion in codon 76 found in the SK-MEL-33 melanoma cell line was found also in the melanoma lesion (Fig. 7) .
Induction ofHLA class I antigen expression on SK-MEL-33 melanoma cells by transfection with human wild-type B2m gene. To prove that the lack of HLA class I antigen expression by SK-MEL-33 cells was caused only by the structural abnormality of j2-,u that we have described, we determined whether transfection of SK-MEL-33 cells with a wild-type human B2m gene could induce HLA class I antigen expression. Six clones were isolated after transfection and selection with the antibiotic G4 18-sulfate. Cells from five ofthe six clones reacted, although to a different extent, with '251-labeled anti-HLA class I mAb W6 / 32 and anti-,B2-/ mAb NAMB-1 ( Table I ). The reactivity is specific since the transfected cells continued to be unreactive with the anti-HLA-DR, DQ, DP mAb Q5/ 13. Furthermore, neither mAb W6/32 nor mAb NAMB-l reacted with melanoma cells SK-MEL-33 transfected with the pSV2neo gene alone.
Discussion
Serological and immunochemical analysis with monoclonal and polyclonal xenoantibodies has shown that cultured melanoma cells SK-MEL-33 do not express HLA class I antigens on their cell surface and do not acquire them after incubation with IFN-'y. This abnormality reflects the synthesis of a truncated ,32-,u that does not associate with HLA class I heavy chains.
Since association with t2-4 is required for the transport ofHLA class I heavy chains to cell membrane (38, 39) , HLA class I heavy chains that are synthesized by melanoma cells SK-MEL-33 remain in the cytoplasm and are not expressed on the cell surface. This conclusion is supported by the results ofimmunoprecipitation experiments performed with an extract of intrinsically radiolabeled melanoma cells SK-MEL-33 and anti-HLA class I mAb with distinct specificities. HLA class I heavy chains are immunoprecipitated by mAb TP25.99, which recognizes a determinant expressed also on ,32-ji-free HLA class I A C G T Figure 7 . Direct sequence analysis of *.
the region surrounding codon 76 of the B2m gene in the surgically removed melanoma lesion from which the cell line SK-MEL-33 was origi- (20, 45) because of a point mutation in the initiation codon (46) . Cultured melanoma cells FO-1 do not transcribe the B2m gene because of a deletion of the first exon, of the 5'-flanking region, and of a segment ofthe first intron ofthe B2m gene (8) . A similar defect has been identified in four mouse cell lines derived from the C48 mouse thymoma cell line R 1.l by chemical or irradiation mutagenesis and subsequent selection with anti-TL antisera and complement (47) (48) (49) . Interestingly, a similar treatment of cultured human B lymphoblastoid cells has caused the mutations ofgenes located in the HLA class II region which control the HLA class I antigen presentation pathway (50, 5 1 
